# US 2004/0204394 A1 · Triptolide analogues

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0204394 A1
- Document ID: US20040204394A1
- Status: Published application
- Kind: A1
- Application number: 10/411,365
- Filed: 2003-04-11
- Published: 2004-10-14
- Earliest claimed: 2003-04-11
- Assignees: Aderis Pharmaceuticals, Inc.
- Inventors: Gevork Minaskanian
- Web page: https://patentgrep.com/patent/US20040204394A1

## CPC

- C07D 493/10: Spiro-condensed systems
- C07D 303/32: by aldehydo- or ketonic radicals
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Triptolide analogues are described, including compounds of Formula I: 1 or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R3-R6, X and Y are set forth in the specification. The compounds of the invention are potent 15-lipoxygenase inducers. Pharmaceutical compositions of the compounds are also described. Also provided are methods for the treatment or prophylaxis of inflammatory and autoimmune disorders in a mammal by administering compounds of the invention.

## Claims

### Claim 1

A compound of Formula I:
37
or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein:
(a) each dotted line indicates the presence of either a single bond or double bond, wherein the valences of a single bond are completed by hydrogens;
(b) X is O, S, or NR11, where R11 is hydrogen or alkyl;
(c) R3, R4, R5, and R6 are independently hydrogen or alkyl;
(d) R12 is hydrogen, alkyl, carboxylalkyl, or R12 is absent; and
(e) Y, together with the two ring carbon atoms to which it is attached, represents a 5- to 7-membered monocyclic carbon ring which is saturated, partially saturated, or aromatic.

### Claim 2 (depends on 1)

A compound of claim 1, wherein X is O.

### Claim 3 (depends on 1)

A compound of claim 1, wherein Y is phenyl or cyclohexyl.

### Claim 4 (depends on 1)

A compound of claim 1, wherein R3, R4, R5, and R6 are independently hydrogen.

### Claim 5 (depends on 1)

A compound of claim 1, wherein Y is phenyl and R3, R4, R5, and R6 are each hydrogen.

### Claim 6 (depends on 1)

A compound of claim 1 that is one of:
38
or a solvate, hydrate or pharmaceutically acceptable salt thereof.

### Claim 7

A compound of Formula II:
39
or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein:
(a) the dotted line indicates the presence of either a single bond or double bond, wherein the valences of a single bond are completed by hydrogens;
(b) X is O, S, or NR11, where R11 is hydrogen or alkyl;
(c) R1, R4, R5, and R6 are independently hydrogen or alkyl;
(d) R12 is hydrogen, alkyl, carboxylalkyl, or R12 is absent; and
(e) Y, together with the two ring carbon atoms to which it is attached, represents a 5- to 7-membered monocyclic carbon ring which can be saturated, partially saturated, or aromatic.

### Claim 8 (depends on 7)

The compound of claim 7, wherein X is O.

### Claim 9 (depends on 7)

The compound of claim 7, wherein R1, R4, R5, and R6 are independently hydrogen.

### Claim 10 (depends on 7)

The compound of claim 7, wherein Y is phenyl.

### Claim 11 (depends on 7)

The compound of claim 7 that is
40
or a solvate, hydrate or pharmaceutically acceptable salt thereof.

### Claim 12

A compound of Formula III:
41
or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein:
(a) X is O, S, or NR11, where R11 is hydrogen or alkyl;
(b) R1, R2, R5, and R6 are independently hydrogen or alkyl;
(c) R12 is hydrogen, alkyl, carboxylalkyl, or R12 is absent; and
(d) Y, together with the two ring carbon atoms to which it is attached, represents a 5- to 7-membered monocyclic carbon ring which can be saturated, partially saturated, or aromatic.

### Claim 13 (depends on 12)

The compound of claim 12, wherein X is O.

### Claim 14 (depends on 12)

The compound of claim 12, wherein R1, R2, R5, and R6 are each hydrogen.

### Claim 15 (depends on 12)

The compound of claim 12, wherein Y is phenyl.

### Claim 16 (depends on 12)

The compound of claim 12 that is
42
or a solvate, hydrate or pharmaceutically acceptable salt thereof.

### Claim 17

A compound of Formula IV:
43
or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein:
(a) X is O, S, or NR11, where R11 is hydrogen or alkyl;
(b) R5 and R6 are independently hydrogen or alkyl;
(c) R12 is hydrogen, alkyl, carboxylalkyl, or R12 is absent; and
(d) Y1 and Y2 each represent, together with the two ring carbon atoms to which each is attached, a 5- to 7-membered monocyclic carbon ring which can be saturated, partially saturated, or aromatic.

### Claim 18 (depends on 17)

The compound of claim 17, wherein X is O.

### Claim 19 (depends on 17)

The compound of claim 17, wherein R5 and R6 are each hydrogen.

### Claim 20 (depends on 17)

The compound of claim 17, wherein Y1 and Y2 are each C6 aryl.

### Claim 21 (depends on 17)

The compound of claim 17 that is
44
or a solvate, hydrate or pharmaceutically acceptable salt thereof.

### Claim 22

A compound of Formula V:
45
or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein:
(a) the dotted line indicates the presence of either a single bond or double bond, wherein the valences of a single bond are completed by hydrogens;
(b) X is O, S, or NR11, where R11 is hydrogen or alkyl;
(c) R5, R7, R8, R9, and R10 are independently hydrogen or alkyl;
(d) R12 is hydrogen, alkyl, carboxylalkyl, or R12 is absent;
(e) Y1 represents, together with the two ring carbon atoms to which it is attached, a 5- to 7-membered monocyclic carbon ring which can be saturated, partially saturated, or aromatic; and
(f) Y2 represents, together with the three ring carbon atoms to which it is attached, a 5- to 7-membered monocyclic carbon ring which can be saturated, partially saturated, or aromatic.

### Claim 23 (depends on 22)

The compound of claim 22, wherein X is O.

### Claim 24 (depends on 22)

The compound of claim 22, wherein R5, R7, R8, R9, and R10 are each hydrogen.

### Claim 25 (depends on 22)

The compound of claim 22, wherein Y1 and Y2 are each phenyl.

### Claim 26 (depends on 22)

The compound of claim 22 that is
46
or a solvate, hydrate or pharmaceutically acceptable salt thereof.

### Claim 27

A compound of Formula VI:
47
or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein:
(a) the dotted line indicates the presence of either a single bond or double bond, wherein the valences of a single bond are completed by hydrogens;
(b) X1 and X2 are independently O, S, or NR11, where R11 is hydrogen or alkyl;
(c) R3, R4, R1 and R6 are independently hydrogen or alkyl;
(d) R12 is hydrogen, alkyl, carboxylalkyl, or R12 is absent; and
(e) Y, together with the two ring carbon atoms to which it is attached, represents a 5- to 7-membered monocyclic carbon ring which can be saturated, partially saturated, or aromatic.

### Claim 28 (depends on 27)

The compound of claim 27, wherein .X1 and X2 are each O.

### Claim 29 (depends on 27)

The compound of claim 27, wherein R3, R4, R1 and R6 are independently hydrogen.

### Claim 30 (depends on 27)

The compound of claim 27, wherein Y is phenyl.

### Claim 31 (depends on 27)

The compound of claim 27 that is one of:
48
or a solvate, hydrate or pharmaceutically acceptable salt thereof.

### Claim 32

A compound of Formula VII:
49
or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein:
(a) X1 and X3 are independently O, S, or NR11, where R11 is hydrogen or alkyl;
(b) R1, R2, R5, and R6 are independently hydrogen or alkyl;
(c) R12 is hydrogen, alkyl, carboxylalkyl, or R12 is absent; and
(d) Y, together with the two ring carbon atoms to which it is attached, represents a 5- to 7-membered monocyclic carbon ring which can be saturated, partially saturated, or aromatic.

### Claim 33 (depends on 32)

The compound of claim 32, wherein X1 and X3 are independently O.

### Claim 34 (depends on 32)

The compound of claim 32, wherein R1, R2, R5, and R6 are independently hydrogen.

### Claim 35 (depends on 32)

The compound of claim 32, wherein Y is phenyl.

### Claim 36 (depends on 32)

The compound of claim 32 that is
50
or a solvate, hydrate or pharmaceutically acceptable salt thereof.

### Claim 37

A compound of Formula VIII:
51
or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein:
(a) the dotted line indicates the presence of either a single bond or double bond, wherein the valences of a single bond are completed by hydrogens;
(b) X1 and X2 are independently O, S, or NR11, where R11 is hydrogen or alkyl;
(c) R3 and R5 are independently hydrogen or alkyl;
(d) R12 is hydrogen, alkyl, carboxylalkyl, or R12 is absent;
(e) Y, together with the two ring carbon atoms to which it is attached, represents a 5- to 7-membered monocyclic carbon ring which can be saturated, partially saturated, or aromatic; and
(f) n is from 3 to 5.

### Claim 38 (depends on 37)

The compound of claim 37, wherein X1 and X2 are each O.

### Claim 39 (depends on 37)

The compound of claim 37, wherein Y is phenyl.

### Claim 40 (depends on 37)

The compound of claim 37, wherein R3 and R5 are each hydrogen and n is 4.

### Claim 41 (depends on 37)

The compound of claim 37 that is
52
or a solvate, hydrate or pharmaceutically acceptable salt thereof.

### Claim 42

A compound of Formula IX:
53
or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein:
(a) X1 and X3 are independently O, S, or NR11, where R11 is hydrogen or alkyl;
(b) R3, R4, R5, and R6 are independently hydrogen or alkyl;
(c) R12 is hydrogen, alkyl, carboxylalkyl, or R12 is absent; and
(d) n is from 3 to 5.

### Claim 43 (depends on 42)

The compound of claim 42, wherein X1 and X3 are each O.

### Claim 44 (depends on 42)

The compound of claim 42, wherein n is 4.

### Claim 45 (depends on 42)

The compound of claim 42 that is
54
or a solvate, hydrate or pharmaceutically acceptable salt thereof.

### Claim 46

A compound of Formula X:
55
or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein:
(a) X1, X2, and X3 are independently O, S, or NR11, where R11 is hydrogen or alkyl;
(b) R3, R4, R5, and R6 are independently hydrogen or alkyl;
(c) R12 is hydrogen, alkyl, carboxylalkyl, or R2 is absent; and
(d) n is from 3 to 5.

### Claim 47 (depends on 46)

The compound of claim 46, wherein X1, X2, and X3 are each O.

### Claim 48 (depends on 46)

The compound of claim 46, wherein n is 4.

### Claim 49 (depends on 46)

The compound of claim 46 that is
56
or a solvate, hydrate or pharmaceutically acceptable salt thereof.

### Claim 50

A compound of Formula XI:
57
or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein:
(a) X1, X2, and X3 are independently O, S, or NR11, where R11 is hydrogen or alkyl;
(b) R5, R6, and R7 are independently hydrogen or alkyl; and
(c) n and n′ are each from 3 to 5.

### Claim 51 (depends on 50)

The compound of claim 50, wherein X1, X2, and X3 are each O.

### Claim 52 (depends on 50)

The compound of claim 50, wherein R5, R6, and R7 are each hydrogen.

### Claim 53 (depends on 50)

The compound of claim 50, wherein n and n′ are each 4.

### Claim 54 (depends on 50)

The compound of claim 50 that is
58
or a solvate, hydrate or pharmaceutically acceptable salt thereof.

### Claim 55

A compound of Formula XII:
59
or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein:
(a) X1, X2, and X3 are independently O, S, or NR11, where R11 is hydrogen or alkyl;
(b) R5 and R7 are independently hydrogen or alkyl; and
(c) n, n′ and n″ are each from 3 to 5.

### Claim 56 (depends on 55)

The compound of claim 55, wherein X1, X2, and X3 are each O.

### Claim 57 (depends on 55)

The compound of claim 55, wherein R5 and R7 are each hydrogen.

### Claim 58 (depends on 55)

The compound of claim 55, wherein n, n′, and n″ are each 4.

### Claim 59 (depends on 55)

The compound of claim 55 that is
60
or a solvate, hydrate or pharmaceutically acceptable salt thereof.

### Claim 60

A compound of Formula XIII:
61
or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein:
(a) X1, X2, and X3 are independently O, S, or NR11, where R11 is hydrogen or alkyl;
(b) R3, R5, and R7 are independently hydrogen or alkyl; and
(c) n and n′ are each from 3 to 5.

### Claim 61 (depends on 60)

The compound of claim 60, wherein X1, X2, and X3 are each O.

### Claim 62 (depends on 60)

The compound of claim 60, wherein R3, R5, and R7 are each hydrogen.

### Claim 63 (depends on 60)

The compound of claim 60, wherein n and n′ are each 4.

### Claim 64 (depends on 60)

The compound of claim 60 that is
62
or a solvate, hydrate or pharmaceutically acceptable salt thereof.

### Claim 65

A compound of Formula XIV:
63
or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein:
(a) X is O, S, or NR11, where R11 is hydrogen or alkyl;
(b) R2, R3, R4, R5, and R6 are independently hydrogen or alkyl; and
(c) n is from 3 to 5.

### Claim 66 (depends on 65)

The compound of claim 65, wherein X is O.

### Claim 67 (depends on 65)

The compound of claim 65, wherein R2, R3, R4, R5, and R6 are each hydrogen.

### Claim 68 (depends on 65)

The compound of claim 65, wherein n is 4.

### Claim 69 (depends on 65)

The compound of claim 65 that is
64
or a solvate, hydrate or pharmaceutically acceptable salt thereof.

### Claim 70

A compound of Formula XV:
65
or a solvate, hydrate or pharmaceutically acceptable salt thereof, wherein:
(a) X1 and X3 are independently O, S, or NR11, where R11 is hydrogen or alkyl; and
(b) R1, R2, R3, R4, R4a, R5, R6, and R7 are independently hydrogen or alkyl.

### Claim 71 (depends on 70)

The compound of claim 70, wherein X1 and X3 are each O.

### Claim 72 (depends on 70)

The compound of claim 70, wherein R1, R2, R3, R4, R4, R5, R6, and R7 are each hydrogen.

### Claim 73 (depends on 70)

The compound of claim 70 that is
66
or a solvate, hydrate or pharmaceutically acceptable salt thereof.

### Claim 74

A compound of Formula XVI:
67
or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein:
(a) X1, X2, and X3 are independently O, S, or NR11, where R11 is hydrogen or alkyl;
(b) R2, R3, and R5 are independently hydrogen or alkyl; and
(c) n and n′ are each from 3 to 5.

### Claim 75 (depends on 74)

The compound of claim 74, wherein X1, X2, and X3 are each O.

### Claim 76 (depends on 74)

The compound of claim 74, wherein R2, R3, and R5 are each hydrogen.

### Claim 77 (depends on 74)

The compound of claim 74, wherein n and n′ are each 4.

### Claim 78 (depends on 74)

The compound of claim 74 that is
68
or a solvate, hydrate or pharmaceutically acceptable salt thereof.

### Claim 79

A compound of Formula XVII:
69
or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein:
(a) X1, X2, and X3 are independently O, S, or NH;
(b) R2, R3, R4, and R5 are independently hydrogen or alkyl;
(c) R12 is hydrogen, alkyl, carboxylalkyl, or R12 is absent; and
(d) Y, together with the two ring carbon atoms to which it is attached, represents a 5- to 7-membered monocyclic carbon ring which is saturated, or partially saturated.

### Claim 80 (depends on 79)

A compound of claim 79, wherein X1, X2, and X3 are each O.

### Claim 81 (depends on 79)

A compound of claim 79, wherein R2, R3, R4, and R5 are each hydrogen.

### Claim 82 (depends on 79)

The compound of claim 79, wherein Y is cyclohexyl.

### Claim 83 (depends on 79)

The compound of claim 79 that is:
70

### Claim 84 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)

A pharmaceutical composition comprising a compound of any of claims 1-83 and a pharmaceutically acceptable carrier.

### Claim 85 (depends on 84)

A method for the treatment of prophylaxis of an inflammatory disorder in a mammal in need thereof, comprising administering to said mammal an effective amount of a composition of claim 84.

### Claim 86 (depends on 84)

A method for the treatment or prophylaxis of an autoimmune disorder in a mammal in need thereof, comprising administering to said mammal an effective amount of a composition of claim 84.
